Parkinson's Disease Center and Movement Disorders Clinic

Size: px
Start display at page:

Download "Parkinson's Disease Center and Movement Disorders Clinic"

Transcription

1 Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas phone Botulinum Toxin Botulinum toxin (BTX) has been used at Baylor College of Medicine Movement Disorders Clinic in the treatment of dystonia and related disorders since Its safety and efficacy has been established, partly as a result of the pioneering work at the Movement Disorder Clinic. The first double-blind, placebo controlled trial of BTX in cranial-cervical dystonia was conducted at Baylor and the findings were used to obtain the initial approval for BTX by the Food and Drug Administration. Dystonia is a neurological condition manifested by involuntary contractions (spasms) of muscles producing twisting, squeezing or pulling movements and abnormal postures. Examples of dystonia include blepharospasm (spasms of eyelids causing involuntary eye closure), cervical dystonia or torticollis (spasms of neck muscles causing twisting and other movements of the neck, abnormal head posture, and neck pain), laryngeal dystonia or spasmodic dysphonia (spasms of vocal cords causing a strained or breathy voice), oromandibular (mouth and jaw spasms) dystonia, and task-specific dystonias (writer's cramps). In addition to dystonias, BTX has been used also to relieve other focal spasms, such as hemifacial spasms, tremors, tics, spasticity, and other movement disorders. At Baylor Movement Disorders Clinic, BTX has been also used to treat muscle contraction (tension) and migraine headaches, excessive drooling (sialorrhea), excessive sweating (hyperhidrosis), and other conditions for which BTX has been found to be effective. Studies involving thousands of patients have demonstrated the usefulness and safety of BTX treatments in these conditions. BTX is a protein that acts by binding to certain nerve endings thus preventing the release of the neurotransmitter acetylcholine. An injection of BTX into the muscle blocks transmission of impulses from the nerve to the muscle causing local and temporary weakness of the target muscle. This process, called 1

2 "chemodenervation," provides effective relief of dystonias and other disorders manifested by abnormal and unwanted muscular contractions or abnormal secretions. The onset of improvement is often noted within a few days after injection and the benefits usually wear off after 3 to 6 months at which time a repeat injection is needed. Because BTX acts only locally without spreading into the circulation, it does not usually cause any systemic reactions. Most patients obtain safe and substantial relief, but a few experience side effects after the treatment. Except for occasional temporary feeling of generalized malaise and weakness, nearly all other side effects are confined to the injected body part. Injections into the eyelids, for example, may result in transient local swelling, droopy eyelids, blurring of vision, and tearing. Injections into the neck muscles may cause temporary neck weakness or pain and difficulties with swallowing. Swallowing problems as well as chewing, speech and voice difficulties may also result from injections into the jaw and vocal cord muscles. Injections into the arm or hand muscles may cause temporary weakness of fingers and hands. These side effects are usually mild, occur infrequently, and most resolve in a few weeks without any specific treatment. If swallowing problems occur, it is advisable to change to a soft or liquid diet. Any troublesome side effects should be reported to the treating or primary care physician. BTX treatments do not represent a cure, but they usually provide satisfactory relief of symptoms that can be maintained by repeating treatments when the effects of previous BTX injections begin to wear off. Rarely, some patients become unresponsive to the treatment because they develop blocking antibodies. Such immunoresistance is quite uncommon and occurs only after repeated treatments, usually with relatively high doses or when injected more frequently than every 2-3 months. There are several ways that the presence of immunoresistance can be detected. The simplest and least expensive way is to inject small amounts of BTX into the inner portion of right eyebrow. If the eyebrow is weakened by the injection and one week later the patient is unable to contract the muscle on that side while frowning, this indicates that the patient does not have blocking antibodies no immunoresistance. Besides this unilateral brow injection (UBI), BTX antibodies can 3

3 be also detected by a mouse bioassay. This test involves sending a frozen blood serum to Northview Pacific Laboratories, th St., Berkeley, CA 94710, (510) When the blood sample is forwarded to the Northview Pacific Laboratories by physicians other than those at Baylor, it is important that you are identified as a patient at Baylor College of Medicine and that the results are forwarded to us. Patients who have become immunoresistant as a result of BTX antibodies no longer respond to subsequent injections with the same type of BTX-A, but may respond to other types of BTX. In December 1989, after extensive laboratory and clinical testing of BTX-A (Botox, Allergan Pharmaceuticals, California) the Food and Drug Administration approved this biologic as a therapeutic agent in patients with strabismus, blepharospasm and other facial nerve disorders, including hemifacial spasm. In December 2000, the FDA approved Botox and BTX-B (MYOBLOC, Solstice Neurosciences, Inc., California) as a treatment for cervical dystonia. In 2002, FDA also approved Botox for treatment of frown lines between the brows and in 2004 BTX was approved for severe underarm sweating (hyperhidrosis). In 2010, Botox received approval for spasticity and headaches. Other indications are still pending. Two variants of botulinum toxin A (Dysport and Xeomin ) were recently introduced to the market in 2009 and 2010 respectively. Both are indicated to treat cervical dystonia in Botox naïve and previously treated patients. Changes in the chemical structure of the botulinum toxin A are being evaluated to promote a shorter onset of effect, but generated shorter duration of benefit. The procedure requires specialized skills and, therefore, only some centers are performing this treatment. The actual cost of the medication and procedure depends on the total dose and sites required to treat the specific condition and will be determined at the time of the visit. To cover the cost of the medication and our overhead, we require that all charges for the medication and for the procedure must be paid or a documentation of pre-approval is presented before the treatment visit. Diagnostic Codes for Filing Insurance Claims 4

4 We are genuinely concerned about the cost of the BTX treatments and we are trying to keep the cost as low as possible. Due to the FDA approval (at least for some indications), many insurance carriers and Medicare provide reimbursement for the cost of the BTX and the chemodenervation procedure. The following codes should be used for filing claims: Diagnostic Codes for Filling Insurance Claims Diagnosis Diagnostic Code Procedure/Treatment (CPT) Blepharospasm Dystonia Torticollis Hemifacial spasm Tremor Spasmodic dysphonia OnabotulinumtoxinA (BOTOX ) - J0585 RimabotulinumtoxinB (MYOBLOC ) - J3490 AbobotulinumtoxinA (DYSPORT ) - J0568 IncobotulinumtoxinB (XEOMIN ) - Q2040 Selected References Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA.2011;305: Aguirregomozcorta M, Pagonabarraga J, Diaz-Manera J, et al. Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism Relat Disord : Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 2015;125(8): Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxina (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci

5 Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65: Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxina (NT 201, XEOMIN, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1 2): Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012;35(5): Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009;16 Suppl 2:14-8. Jankovic J, Hunter C, Dolimbek BZ, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67: Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8): Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon [Epub ahead of print] Jinnah HA, Comella CL, Perimutter J, Lungu C, Hallett M, Dystonia Coalition Investigators. Longitudinal studies of botulinum toxin in cervical dystonia: why do patients discontinue therapy? Toxicon [Epub ahead of print] Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer's cramp: a randomized, placebo-controlled trial and 1- year follow-up. J Neurol Neurosurg Psychiatry. 2007;78: Lolekha P, Choolam A, Kuklantrakom K. A comparative crossover study of the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques. Neurol Sci [Epub ahead of print] Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord.2005;20: Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum toxin in Parkinson disease tremor: a randomized, double-blind, placebo-controlled study with a customized injection approach. Mayo Clin Proc. 2017;92(9):

6 Ni J, Wang X, Cao N, Si J, Gu B. Is repeat botulinum toxin A injection valuable for neurogenic detrusor overactivity a systematic review and meta-analysis. Neurourol Urodyn [Epub ahead of print] Ramirez-Castaneda J, Jankovic J, Comella C, et al. Diffusion, spread, and migration of botulinum toxin. Mov Disord Nov;28 (13): Samotus O, Lee J, Jog M. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS One. 2017;12(6):1-19. Santamato A, Panza F, Intiso D, Baricich, Picelli A, Smania N, Fortunato F, Seripa D, Fiore P, Ranieri M. Long-term safety of repeated high doses of incobotulinumtoxina injections for the treatment of upper and lower limb spasticity after stroke. J Neurol Sci. 2017;378: Scheps D, de la Paz ML, Jurk M, Hofmann F, Frevert J. Design of modified botulinum neurotoxin A1 variants with a shorter persistence of paralysis and duration of action. Toxicon [Epub ahead of print] Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A; BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebocontrolled study. J Neurol Neurosurg Psychiatry. 2009;80: Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016;86(19): International Neurotoxin Association 7

THE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN

THE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN THE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN Spasmodic torticollis (cervical dystonia), blepharospasm, and writer s cramp are specific types

More information

Parkinson's Disease Center and Movement Disorders Clinic

Parkinson's Disease Center and Movement Disorders Clinic Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Blepharospasm Diagnosis Involuntary facial movements

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other ONABOTULINUMTOXINA BOTOX 04867 BRAND BOTOX COSMETIC ABOBOTULINUMTOXINA DYSPORT 36477 RIMABOTULINUMTOXINB MYOBLOC 21869 INCOBOTULINUMTOXINA XEOMIN 36687 Please use

More information

Neuromuscular Blocking Agents

Neuromuscular Blocking Agents Neuromuscular Blocking Agents DRUG POLICY This Prior Authorization request will be reviewed for medical necessity only. Benefits are subject to the terms and conditions of the patient s contract. Please

More information

BOTOX. Description. Section: Prescription Drugs Effective Date: January 1, 2013 Subsection: CNS Original Policy Date: December 7, 2011

BOTOX. Description. Section: Prescription Drugs Effective Date: January 1, 2013 Subsection: CNS Original Policy Date: December 7, 2011 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.12.01 Subject: Botox Page: 1 of 6 Last Review Status/Date: December 6, 2012 BOTOX Description Botox (onabotulinum

More information

Botox. Botox (onabotulinum toxin A) Description

Botox. Botox (onabotulinum toxin A) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 8 Last Review Date: September 15, 2017 Botox Description Botox (onabotulinum

More information

BOTOX (onabotulinumtoxina) for Therapeutic Use

BOTOX (onabotulinumtoxina) for Therapeutic Use BOTOX (onabotulinumtoxina) for Therapeutic Use BOTOX (onabotulinumtoxina) & BOTOX Cosmetic (onabotulinumtoxina) Important Information IMPORTANT SAFETY INFORMATION BOTOX and BOTOX Cosmetic may cause serious

More information

MEDICATION GUIDE BOTOX BOTOX Cosmetic (Boe-tox) (onabotulinumtoxina) for Injection

MEDICATION GUIDE BOTOX BOTOX Cosmetic (Boe-tox) (onabotulinumtoxina) for Injection 17.2 Ability to Operate Machinery or Vehicles Advise patients that if loss of strength, muscle weakness, blurred vision, or drooping eyelids occur, they should avoid driving a car or engaging in other

More information

Botulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc )

Botulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc ) Botulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc ) These services may or may not be covered by your HealthPartners

More information

Hemifacial spasm. Parkinson's Disease Center and Movement Disorders Clinic

Hemifacial spasm. Parkinson's Disease Center and Movement Disorders Clinic Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Hemifacial spasm Diagnosis Hemifacial spasm

More information

Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)

Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date:

More information

Parkinson's Disease Center and Movement Disorders Clinic

Parkinson's Disease Center and Movement Disorders Clinic Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Dystonia Diagnosis Dystonia is a neurologic

More information

Clare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct)

Clare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct) Clare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct) 07935567067 cjg.aesthetics@yahoo.co.uk www.cjgaesthetics.co.uk http://www.facebook.com/cjgaesthetics @CJGAesthetics

More information

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)? Pharmacy Prior Authorization AETA BETTER HEALTH MICHIGA Botulinum Toxins (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign

More information

MYOBLOC and Cervical Dystonia A Patient s Guide

MYOBLOC and Cervical Dystonia A Patient s Guide MYOBLOC and Cervical Dystonia A Patient s Guide MYOBLOC (rimabotulinumtoxinb) Injection is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position

More information

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 4/2/19. IncobotulinumtoxinA

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 4/2/19. IncobotulinumtoxinA IncobotulinumtoxinA NDC CODE(S) 00259-1605-XX Xeomin 50 UNIT SOLR (MERZ PHARMACEUTICAL) 00259-1610-XX Xeomin 100 UNIT SOLR (MERZ PHARMACEUTICAL) 00259-1620-XX Xeomin 200 UNIT SOLR (MERZ PHARMACEUTICAL)

More information

Medication Prior Authorization Form

Medication Prior Authorization Form (OnabotulinumtoxinA) Dysport (abobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Xeomin (incobotulinumtoxina) Policy Number: 1042 Policy History Approve Date: 12/11/2015 Revise Dates: 7/7/2016 Next Review:

More information

Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)

Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Local Coverage Determination (LCD): Drugs and Biologicals: Botulinum Toxins (L34253) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information

More information

Antibody-Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications

Antibody-Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications Antibody-Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications DIRK DRESSLER, MD, PHD, KAI WOHLFAHRT, MD, PHD, y ELLEN MEYER-ROGGE, MD, z LUITGARD WIEST, MD, y AND HANS BIGALKE, MD, PHD

More information

Botox. Botox (onabotulinum toxin A) Description

Botox. Botox (onabotulinum toxin A) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 10 Last Review Date: November 30, 2018 Botox Description Botox (onabotulinum

More information

Table of Contents. 1.0 Description of the Procedure, Product, or Service Safety and Provider Compliance... 1

Table of Contents. 1.0 Description of the Procedure, Product, or Service Safety and Provider Compliance... 1 Table of Contents 1.0 Description of the Procedure, Product, or Service... 1 1.1 Safety and Provider Compliance... 1 2.0 Eligibility Requirements... 1 2.1 Provisions... 1 2.1.1 General... 1 2.1.2 Specific...

More information

Botox , The Patient Education Institute, Inc. rxf60101 Last reviewed: 01/11/2018 1

Botox , The Patient Education Institute, Inc.  rxf60101 Last reviewed: 01/11/2018 1 Botox Introduction Botox is a well known brand name for a medicinal form of a toxin, or poison. When injected in small doses into specific muscles, Botox doesn't poison you. Instead, it acts as a muscle

More information

Harald Hefter, 1 Christian Hartmann, 1 Ulrike Kahlen, 1 Marek Moll, 1 Hans Bigalke 2

Harald Hefter, 1 Christian Hartmann, 1 Ulrike Kahlen, 1 Marek Moll, 1 Hans Bigalke 2 Open Access Research Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins a single

More information

Circle Yes or No Y N. [If yes, no further questions.]

Circle Yes or No Y N. [If yes, no further questions.] 02/18/2016 Prior Authorization AETA BETTER HEALTH PE MEDICAID & AETA BETTER HEALTH KIDS Botulinum Toxins (PA88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

Informed Consent Form

Informed Consent Form Informed Consent Form Botox Cosmetic (onabotulinumtoxin A) Dysport (abobotulinumtoxin A) Xeomin (incobotulinumtoxin A) INSTRUCTIONS This is an informed-consent document that has been prepared to help inform

More information

MERZ NEUROSCIENCES to PRESENT XEOMIN (incobotulinumtoxina) DATA AT THE 21 ST INTERNATIONAL CONGRESS OF PARKINSON S DISEASE AND MOVEMENT DISORDERS

MERZ NEUROSCIENCES to PRESENT XEOMIN (incobotulinumtoxina) DATA AT THE 21 ST INTERNATIONAL CONGRESS OF PARKINSON S DISEASE AND MOVEMENT DISORDERS MERZ NEUROSCIENCES to PRESENT XEOMIN (incobotulinumtoxina) DATA AT THE 21 ST INTERNATIONAL CONGRESS OF PARKINSON S DISEASE AND MOVEMENT DISORDERS MERZ TO PRESENT FIVE POSTERS INCLUDING LATE BREAKER RALEIGH,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: botulinum_toxin_injection 8/1985 10/2017 10/2018 10/2017 Description of Procedure or Service Description

More information

IN ADUL T SUBJECTS WITH BLEPHAROSPASM ACROSS DOSING INTE R VAL S

IN ADUL T SUBJECTS WITH BLEPHAROSPASM ACROSS DOSING INTE R VAL S Poster number 609 INCOBOT UL INUMT OXINA (NT -201) I NJ E C T I ONS A R E SAFE AND EFFECTIVE IN ADUL T SUBJECTS WITH BLEPHAROSPASM ACROSS DOSING INTE R VAL S IN A REPEATED DOSE ST UDY Matthew Brodsky,

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium clostridium botulinum neurotoxin type A, 100 unit powder for solution for injection (Xeomin ) No. (464/08) Merz Pharma UK Ltd 09 May 2008 The Scottish Medicines Consortium

More information

Clinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: CP.PHAR.231

Clinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: CP.PHAR.231 Clinical Policy: (Xeomin) Reference Number: CP.PHAR.231 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Prior Authorization Update: Botulinum Toxins

Prior Authorization Update: Botulinum Toxins Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

D. M. Simpson, A. Blitzer, A. Brashear, et al. DOI /01.wnl This information is current as of May 5, 2008

D. M. Simpson, A. Blitzer, A. Brashear, et al. DOI /01.wnl This information is current as of May 5, 2008 Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

More information

Clinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: ERX.SPA.194 Effective Date:

Clinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: ERX.SPA.194 Effective Date: Clinical Policy: (Xeomin) Reference Number: ERX.SPA.194 Effective Date: 01.11.17 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex)

DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex) DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex) CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Dysport. It does not contain all

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Xeomin) Reference Number: CP.PHAR.231 Effective Date: 07.01.16 Last Review Date 05.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder

More information

Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies

Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies 612 Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA P A Hanna J Jankovic Neurosciences Group, Department of Clinical Neurology,

More information

& MIGRAINE DIARY YOUR HEADACHE. Talk with your doctor about BOTOX and Chronic Migraine

& MIGRAINE DIARY YOUR HEADACHE. Talk with your doctor about BOTOX and Chronic Migraine YOUR HEADACHE & MIGRAINE DIARY Do you really know how many headaches and migraines you have in a month? Keeping a diary like this one can help you find out. If you have 15 or more headache days a month,

More information

Medication Prior Authorization Form

Medication Prior Authorization Form (OnabotulinumtoxinA) Dysport (abobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Xeomin (incobotulinumtoxina) Policy Number: 1042 Policy History Approve Date: 12/11/2015 Revise Dates: 07/07/2017 Next Review:

More information

Headache and Migraine Treatment

Headache and Migraine Treatment Many of us think of Botox primarily as a cosmetic treatment for lines and wrinkles on the face, but the botulinum toxin that Botox is derived from has a long history of medically therapeutic uses. In fact,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: botulinum_toxin_injection 8/1985 10/2015 10/2016 10/2015 Description of Procedure or Service Description

More information

DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex)

DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex) DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex) CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Dysport. It does not contain all

More information

We have been hearing about the Botulinum. Role of Botulinum toxin injection in neurological problems: A Short Review

We have been hearing about the Botulinum. Role of Botulinum toxin injection in neurological problems: A Short Review Review Article Isha Dhungana, MD, PhD Neurology Unit Neuro Center and Polyclinic Prabin Shrestha, MD, PhD Department of Neurosurgery Norvic International Hospital Address for correspondence: Isha Dhungana,

More information

WARNING: DISTANT SPREAD OF TOXIN EFFECT

WARNING: DISTANT SPREAD OF TOXIN EFFECT Dear Doctor, We have enclosed a sample XEOMIN (incobotulinumtoxina) treatment patient consent form for your information. Please be aware that this form is merely intended for use as an example. Merz Aesthetics,

More information

BOTULINUM TOXINS A AND B

BOTULINUM TOXINS A AND B DRUG POLICY BOTULINUM TOXINS A B Policy Number: 2014D0017N Effective Date: 9/1/2014 Table of Contents Page COVERAGE RATIONALE... 1 BENEFIT CONSIDERATIONS... 7 BACKGROUND... 8 CLINICAL EVIDENCE... 8 U.S.

More information

Abbreviated Class Review: Botulinum toxins

Abbreviated Class Review: Botulinum toxins Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Pharmacy Medical Necessity Guidelines: Botulinum Toxins

Pharmacy Medical Necessity Guidelines: Botulinum Toxins Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Effective: Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical

More information

Original Policy Date

Original Policy Date MP 5.01.03 Botulinum Toxin Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index

More information

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

See Policy CPT/HCPCS CODE section below for any prior authorization requirements Effective Date: 4/1/2017 Section: MED Policy No.: 209 Medical Officer 4/1/2018 Date Technology Assessment Committee Approved Date: 4/09;6/10, 01/11; 5/13; 2/15 Medical Policy Committee Approved Date: 11/09;

More information

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)? Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Botulinum Toxins (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and

More information

Botulinum Toxin Therapy Billing & Coding Update 2016

Botulinum Toxin Therapy Billing & Coding Update 2016 Botulinum Toxin Therapy Billing & Coding Update 2016 Martin Taylor, DO, PhD Neurology / OrthoNeuro Clinical Associate Professor, Neurology Ohio University College of Osteopathic Medicine Columbus, OH Disclosures

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Botulinum Toxins Reference Number: TCHP.PHAR.1812 Effective Date: 07.01.2018 Last Review Date: 04.13.2018 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the

More information

CONSUMER MEDICINE INFORMATION

CONSUMER MEDICINE INFORMATION CONSUMER MEDICINE INFORMATION BOTOX (botulinum toxin, type A) purified neurotoxin complex The information in this leaflet is ONLY a summary and is not a complete statement about BOTOX injection. Your doctor

More information

Botulinum Toxins (BOTOX, DYSPORT, MYOBLOC and XEOMIN)

Botulinum Toxins (BOTOX, DYSPORT, MYOBLOC and XEOMIN) Botulinum Toxins (BOTOX, DYSPORT, MYOBLOC and XEOMIN) Policy Number: Original Effective Date: MM.04.004 03/14/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 10/01/2013 Section: Prescription

More information

For peer review only. BMJ Open. For peer review only -

For peer review only. BMJ Open. For peer review only - Decline in neutralising antibody titres in secondary nonresponders despite continuous treatment with a botulinum neurotoxin type A preparation free of complexing proteins Journal: Manuscript ID: bmjopen-0-000

More information

(ONABOTULINUMTOXINA) RECEIVES U.S

(ONABOTULINUMTOXINA) RECEIVES U.S BOTOX (ONABOTULINUMTOXINA) RECEIVES U.S. FDA APPROVAL FOR THE TREATMENT OF URINARY INCONTINENCE IN ADULTS WITH NEUROLOGICAL CONDITIONS INCLUDING MULTIPLE SCLEROSIS AND SPINAL CORD INJURY Clinical Trials

More information

BOTOX Cosmetic (onabotulinumtoxina) before-and-after photo files

BOTOX Cosmetic (onabotulinumtoxina) before-and-after photo files BOTOX Cosmetic (onabotulinumtoxina) before-and-after photo files INSTRUCTIONS FOR USE This zip file contains PDF files with images and Important Safety Information to copy and paste into your practice

More information

Disclaimer. All information shared in this presentation is in the public domain.

Disclaimer. All information shared in this presentation is in the public domain. THE BOTOX STORY Disclaimer All information shared in this presentation is in the public domain. Hence, no trade secret related to drug formulation, manufacturing process, commercial practice, etc. The

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Local Coverage Determination (LCD): Botulinum Toxins (L33274) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information CONTRACTOR NAME

More information

ALTERNATIVE TREATMENTS

ALTERNATIVE TREATMENTS Botox Consent INSTRUCTIONS This is an informed- consent document which has been prepared to help your plastic surgeon inform you concerning BOTOX (Botulina Toxin Type A, Allergan) injection, its risks,

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Clostridium botulinum neurotoxin type A haemagglutinin complex Pharmaceutical form(s)/strength: powder for solution for injection, 300 unit and 500 unit P-RMS:

More information

BOTOX Cosmetic (onabotulinumtoxina) before-and-after

BOTOX Cosmetic (onabotulinumtoxina) before-and-after BOTOX Cosmetic (onabotulinumtoxina) before-and-after Moderate to severe crow s feet lines Before After (Day 7) Actual patient. Results may vary. Photos taken at full smile before and after treatment with

More information

Scientific Update Laxman Bahroo, MD

Scientific Update Laxman Bahroo, MD Scientific Update Laxman Bahroo, MD Associate Professor Director; Botulinum Toxin Clinic Director; Neurology Residency Program Medstar Georgetown University Hospital Washington, D.C. Disclosures Advisory

More information

Policy. covered. (spasmodic. Cervical dystonia. injury, or more of. migraine. agents. - Migraine - Migraine. per month. communication, dystonia

Policy. covered. (spasmodic. Cervical dystonia. injury, or more of. migraine. agents. - Migraine - Migraine. per month. communication, dystonia Botulinum Toxin Policy Number: 5.01.05 Origination: 02/1998 Last Review: 02/2014 Next Review: 02/2015 Policy BCBSKC will provide coverage for botulinum toxin A and B injections it is determined to be medically

More information

Botulinum Toxin. When Policy Topic is covered The use of botulinum toxin may be considered medically necessary for the following:

Botulinum Toxin. When Policy Topic is covered The use of botulinum toxin may be considered medically necessary for the following: Botulinum Toxin Policy Number: 5.01.05 Last Review: 01/2018 Origination: 02/1998 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for botulinum toxin

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Dysport) Reference Number: CP.PHAR.230 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder

More information

Articles Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis

Articles Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis Freely available online Articles Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis Daniel Martinez-Ramirez 1, Juan C. Giugni 1, Erin Hastings 1,

More information

DRUG USE EVALUATION: UTILIZATION OF BOTULINUM TOXIN

DRUG USE EVALUATION: UTILIZATION OF BOTULINUM TOXIN There are currently four botulinum toxin (BoNT) products available in the United States: abobotulinumtoxina (ABO), incobotulinumtoxina (INC), onabotulinumtoxina (ONA), and rimabotulinumtoxinb (RIM). They

More information

MEDICATION GUIDE Myobloc (My-o-block) (rimabotulinumtoxinb) Injection

MEDICATION GUIDE Myobloc (My-o-block) (rimabotulinumtoxinb) Injection MEDICATION GUIDE Myobloc (My-o-block) (rimabotulinumtoxinb) Injection Read the Medication Guide that comes with MYOBLOC before you start using it and each time MYOBLOC is given to you. There may be new

More information

SEE IMPORTANT SAFETY INFORMATION ON PAGE 2. See Important Safety Information inside.

SEE IMPORTANT SAFETY INFORMATION ON PAGE 2. See Important Safety Information inside. See Important Safety Information inside. Visit BotoxCosmetic.com to learn more. By prescription only. 1-800-BOTOX-MD Also from the Allergan family of brands: 2010 Allergan, Inc., Irvine, CA 92612. marks

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Xeomin) Reference Number: CP.PHAR.231 Effective Date: 07.01.16 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder

More information

Neurotoxins (Botox, Dysport, Myobloc and Xeomin )

Neurotoxins (Botox, Dysport, Myobloc and Xeomin ) Last Review Date: November 10, 2017 Number: MG.MM.PH.01mC Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Understanding Dystonia

Understanding Dystonia Understanding Dystonia Sand Sharks Anthony Richardsen, Lindsey Rathbun, Evan Harrington, Chris Erzen The Essentials What, Why, How What is Dystonia? Dystonias are movement disorders often characterized

More information

CONSUMER MEDICINE INFORMATION

CONSUMER MEDICINE INFORMATION CONSUMER MEDICINE INFORMATION BOTOX (botulinum toxin, type A) purified neurotoxin complex The information in this leaflet is ONLY a summary and is not a complete statement about BOTOX injection. Your doctor

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Myobloc) Reference Number: CP.PHAR.233 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder

More information

Aetna Better Health of Virginia

Aetna Better Health of Virginia Botox (onabotulinumtoxina) Myobloc (rimabotulinumtoxinb) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Indications: (use if necessary): Overactive Bladder BOTOX indicated for the treatment

More information

Andy was treated for frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside.

Andy was treated for frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside. Andy was treated for frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside. Feel confident that you can still look like yourself With BOTOX

More information

This guide describes some of the important facts about Neurobloc that you need to be aware of, however, it does not replace the advice given to you

This guide describes some of the important facts about Neurobloc that you need to be aware of, however, it does not replace the advice given to you This guide describes some of the important facts about Neurobloc that you need to be aware of, however, it does not replace the advice given to you by a healthcare professional. Further very important

More information

Why is this botulinum toxin prescribed?

Why is this botulinum toxin prescribed? Why is this botulinum toxin prescribed? Botulinum Toxin injections are in a class of medications called neurotoxins. When Botulinum Toxin is injected into a muscle, it blocks the nerve signals that cause

More information

Please see Approved Uses and Important Safety Information, including Boxed Warning, inside.

Please see Approved Uses and Important Safety Information, including Boxed Warning, inside. Please see Approved Uses and Important Safety Information, including Boxed Warning, inside. IT S YOUR STORY, TELL IT YOUR WAY You ve probably heard of BOTOX Cosmetic, but did you know: It s the first and

More information

Cynthia was treated for her frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside.

Cynthia was treated for her frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside. Cynthia was treated for her frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside. Your lines don t define you Get the subtle results you

More information

Professor Tim Anderson

Professor Tim Anderson Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition

More information

Source: *Dystonia facts medically edited by: Charles Patrick Davis, MD, PhD

Source:  *Dystonia facts medically edited by: Charles Patrick Davis, MD, PhD Source: http://www.medicinenet.com/script/main/art.asp?articlekey=349 Dystonia facts* *Dystonia facts medically edited by: Charles Patrick Davis, MD, PhD Dystonia is a disorder of muscle control; it can

More information

Hubert H. Fernandez, MD

Hubert H. Fernandez, MD Hubert H. Fernandez, MD Associate Professor Co-Director, Movement Disorders Center Director, Clinical Trials for Movement Disorders Program Director, Neurology Residency and Movement Disorders Fellowship

More information

Important Safety Information

Important Safety Information Important Safety Information What is the most important information you should know about Oysport? Spread of Toxin Effects: In some cases, the effects of Dysport and all botulinum toxin products may affect

More information

This policy addresses only the type B formulation rimabotulinumtoxinb marketed as Myobloc.

This policy addresses only the type B formulation rimabotulinumtoxinb marketed as Myobloc. RimabotulinumtoxinB NDC CODE(S) 10454-0710-XX Myobloc 2500 UNIT/0.5ML SOLN (SOLSTICE NEUROSCIENCES) 10454-0711-XX Myobloc 5000 UNIT/ML SOLN (SOLSTICE NEUROSCIENCES) 10454-0712-XX Myobloc 10000 UNIT/2ML

More information

Dystonias. How are the dystonias classified? One way of classifying the dystonias is according to the parts of the body they affect:

Dystonias. How are the dystonias classified? One way of classifying the dystonias is according to the parts of the body they affect: Dystonias What are the dystonias? The dystonias are movement disorders in which sustained muscle contractions cause twisting and repetitive movements or abnormal postures. The movements, which are involuntary

More information

Neurological disorders. Dystonia Search date September 2013 Ailsa Snaith and Derick Wade ...

Neurological disorders. Dystonia Search date September 2013 Ailsa Snaith and Derick Wade ... Search date September 213 Ailsa Snaith and Derick Wade.................................................. ABSTRACT INTRODUCTION: is usually a lifelong condition with persistent pain and disability. Focal

More information

Botulinum toxin type A in the treatment of patients with cervical dystonia

Botulinum toxin type A in the treatment of patients with cervical dystonia REVIEW Botulinum toxin type A in the treatment of patients with cervical dystonia Allison Brashear Dept of Neurology, Wake Forest University Baptist, Medical Center, Winston Salem, NC, USA Correspondence:

More information

Please see Important Safety Information, including Boxed Warning, inside.

Please see Important Safety Information, including Boxed Warning, inside. Sandra was treated in her frown lines and crow s feet areas. Results may vary. Please see Important Safety Information, including Boxed Warning, inside. Approved Uses BOTOX Cosmetic (onabotulinumtoxina)

More information

Treating Adults with Cervical Dystonia

Treating Adults with Cervical Dystonia Treating Adults with Cervical Dystonia Learn more about Dysport Talk to your doctor about Dysport and find out if it is right for you. What is Dysport? Dysport is a prescription medicine that is injected

More information

Is OnabotulinumtoxinA Good for Other Head and Face Pain? Disclosures BoNT/A for non- CM Botulinum neurotoxin (BoNT) in clinical use for headache >20

Is OnabotulinumtoxinA Good for Other Head and Face Pain? Disclosures BoNT/A for non- CM Botulinum neurotoxin (BoNT) in clinical use for headache >20 1 2 3 4 5 6 Is OnabotulinumtoxinA Good for Other Head and Face Pain? Disclosures BoNT/A for non- CM Botulinum neurotoxin (BoNT) in clinical use for headache >20 years Efficacy of BoNT type A (onabotulinumtoxina,

More information

INFORMED CONSENT BOTOX INJECTION

INFORMED CONSENT BOTOX INJECTION . Purchasers of the Patient Consultation Resource Book are given a limited license to modify documents contained herein and reproduce the modified version for use in the Purchaser's own practice only.

More information

Informed Consent Botulina Toxins Botox, Dysport, Xeomin Neurotoxins

Informed Consent Botulina Toxins Botox, Dysport, Xeomin Neurotoxins Informed Consent Botulina Toxins - Botox Neurotoxins Informed Consent Botulina Toxins Botox, Dysport, Xeomin Neurotoxins INSTRUCTIONS This is an informed-consent document that has been prepared to help

More information

Albert C. Clairmont, MD Associate Professor-Clinical Department of PM & R The Ohio State University

Albert C. Clairmont, MD Associate Professor-Clinical Department of PM & R The Ohio State University Botulinum Toxin for Movement Disorders: Physiology, Pharmacology and Evaluation of Patients Albert C. Clairmont, MD Associate Professor-Clinical Department of PM & R The Ohio State University OBJECTIVES

More information

Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia

Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia DOI 10.1186/s40064-016-2967-x RESEARCH Open Access Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia Chuanjie Wu 1, Fang Xue 2, Wansheng Chang

More information

Table of Contents. Preface... xi. Part I: Introduction to Movement Disorders

Table of Contents. Preface... xi. Part I: Introduction to Movement Disorders Table of Contents Visit www.healthreferenceseries.com to view A Contents Guide to the Health Reference Series, a listing of more than 14,000 topics and the volumes in which they are covered. Preface...

More information

Clinical Relevance of Botulinum Toxin Immunogenicity

Clinical Relevance of Botulinum Toxin Immunogenicity OPEN ACCESS: CURRENT OPINION Biodrugs 2012; 26 (2): e1-e9 1173-8804/12/0002-0001 ª 2012 Benecke, publisher and licensee Adis Data Information BV. This is an open access article published under the terms

More information